- Home
- TLSA vs MPU Comparison
TLSA vs MPU Comparison
Compare TLSA & MPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | MPU |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United Kingdom | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 14.6M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TLSA | MPU |
|---|---|---|
| Price | $1.06 | $2.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.02 | N/A |
| AVG Volume (30 Days) | ★ 674.2K | 7.0K |
| Earning Date | 05-01-2026 | 12-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.17 |
| 52 Week High | $2.10 | $3.88 |
Technical Indicators
Market Signals| Indicator | TLSA | MPU |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 56.75 |
| Support Level | $0.90 | $0.62 |
| Resistance Level | $1.21 | $2.97 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 39.90 | 10.69 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.